Top

Published in:

01-04-2005 | Current Concepts in Clinical Surgery

Colon cancer: survival after curative surgery

Authors: K. H. Link, T. A. Sagban, M. Mörschel, K. Tischbirek, M. Holtappels, V. Apell, K. Zayed, M. Kornmann, L. Staib

Published in: Langenbeck's Archives of Surgery | Issue 2/2005

Abstract

Several new aspects have evolved during the past years concerning factors that influence survival in surgically and medically treated colon cancer patients that are relevant to the treating team for the treatment strategy and patient’s choice. The 5-year-survival rates dependent on UICC stages/substages (I: 68%–100%, II: 58%–90%, III: 33%–76%, IV: <5%–9%) show remarkable variations between published reports, surgical hospital units, individual surgeons, and continents (USA vs Europe). Those variations may be due to surgical techniques, training status, hospital and individual case volume, and, also, referral patterns and statistical evaluation methods. Survival times and cure rates are significantly improved by adjuvant chemotherapy in UICC III and in substages of UICC II (e.g. UICC II B) by 5%–12%, when compared with surgical controls. In three recently published trials standard adjuvant chemotherapy was further improved by increased survival rates, e.g. from 59% to 71% in stage III and IIB patients. Molecular and genetic factors, such as thymidylate synthase (TS), microsatellite instability (MSI) or loss of chromosome 18q/“DCC” might have an independent impact on prognosis in the spontaneous course, and TS could help to better select patients for adjuvant chemotherapy.

Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland in Zusammenarbeit mit dem Robert Koch Institut (2002) Krebs in Deutschland Häufigkeiten und Trends. Saarbrücken 3. Ausgabe; ISBN 3-88718-153-0

Birkmeyer JD, Siewers AE, Finlayson E, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346:1128–1137CrossRefPubMed

Brenner H, Hakulinen T (2003) On crude and age-adjusted relative survival rates. J Clin Epidemiol 56:1185–1191CrossRefPubMed

Brenner H, Spix C (2003) Combining cohort and period methods for retrospective time trend analyses of long-term cancer patient survival rates. Br J Cancer 89:1260–1265CrossRefPubMed

Brenner H, Arndt V, Stürmer T, Stegmaier C, Ziegler H, Dhom G (2001) Long-lasting reduction of risk of colorectal cancer following screening endoscopy. Br J Cancer 85:972–976CrossRefPubMed

Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP (2000) American joint committee on cancer prognostic factors consensus conference: colorectal working group. Cancer 88:1739–1757CrossRefPubMed

De Gramont A, Banzi M, Navarro M, et al (2003) Oxaliplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized mosaic trial. Proc Am Soc Clin Oncol 22 (abstract 1015)

Ederer F, Axtell LM, Cutler SJ (1961) The relative survival rate: a statistical methodology. Monogr Natl Cancer Inst 6:101–121

Ederer F, Geisser MS, Mongin SJ, Church TR, Mandel JS (1999) Colorectal cancer deaths as determined by expert committee and from death certificate: a comparison. Minnesota Study. J Clin Epidemiol 52:447–452CrossRefPubMed

10.

Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H (2002) Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20:1721–1728CrossRefPubMed

11.

Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, Iacopetta B (2001) P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 7:1343–1349PubMed

12.

Fingerhut A, Msika S, Yahchouchi E, Merad F, Hay JM, Millat B (2000) Neither pelvic nor abdominal drainage is needed after anastomosis in elective, uncomplicated, colorectal surgery. Ann Surg 231:613–614CrossRef

13.

Francini G, Petrioloi R, Lorenzini L, Armenio S, Tanzini G, Marsili S, Aquino A, Marzocca G, Civitelli S, et al (1994) Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 106:899–906PubMed

14.

Gatta G, Capocaccia R, Coleman MP, Gloeckler Ries LA, Hakulinen T, Micheli A, Sant M, Verdecchia A, Berrino F (2000) Toward a comparison of survival in American and European cancer patients. Cancer 89:893–900CrossRefPubMed

15.

Gatta G, Capocaccia R, DeAngelis R, Stiller C, Coebergh JW, the EUROCARE Working Group (2003) Cancer survival in European adolescents and young adults. Eur J Cancer 39:2600–2610CrossRefPubMed

16.

Graupe F, Schwenk F, Bracht B, Kröner-Herwig B, Stock W (1996) Die psychische Belastung von Patienten in der Tumornachsorge nach R0-Resektion colorectaler Carcinome. Chirurg 67:604–610PubMed

17.

Hafstrom L, Domellof L, Rudenstam CM, Norryd C, Bergman L, Hansson K, Whalby L, Asklof G, Kugelberg C (1990) Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes’ C colorectal cancer. The Swedish gastrointestinal tumour adjuvant therapy group. Br J Surg 77:1345–1348

18.

Hakulinen T, Abeywickrama KH (1985) A computer program package for relative survival analysis. Comput Programs Biomed 19:197–207CrossRefPubMed

19.

Haller DG, Catalano PJ, MacDonald JS, et al (1998) Fluorouracil (FU), leucovorin (LV), and levamisole (LEV) adjuvant therapy for colon cancer: five year final report of ITN-0089. Proc Am Soc Clin Oncol 17:256a

20.

Hermanek P (1996) Will-Rogers-Phänomen Fakt oder Fiktion? Chirurg 67:769–770PubMed

21.

Hermanek P, Wiebelt H, et al (1994) Langzeitergebnisse der chirurgischen Therapie des Kolonkarzinoms (Ergebnisse der Studiengruppe Kolorektales Karzinom). Chirurg 65:287–297PubMed

22.

Hermanek P, Mansmann U, Altendorf-Hofmann A, Hermanek P Jr, Riedl S, Staimmer D für die Studiengruppe Kolorektales Karzinom (SGKRK) (1999) Vergleichende Beurteilung der onkologischen Ergebnisqualität beim colorectalen Carcinom. Klinikvergleiche anhand von Surogatendpunkten? Chirurg 70:407–414CrossRefPubMed

23.

Herrera-Ornelas L, Justiniano J, Castillo N, Petrelli NJ, Stulc JP, Mittelman A (1987) Metastases in small lymph nodes from colon cancer. Arch Surg 122:1253–1256

24.

Joseph NE, Sigurdson ER, Hanlon AL, Wang H, Mayer RJ, MacDonald JS, Catalano PJ, Haller DG (2003) Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol 10:213–218CrossRefPubMed

25.

Kaplan E, Meier P (1958) Non-parametric estimation from incomplete observations. Am J Stat Assoc 53:457–481

26.

Kornmann M, Link KH, Lenz HJ, Pillasch J, Metzger R, Buter U, Leder GH, Weindel M, Safi F, Danenberg KD, Beger HG, Danenberg PV (1997) Thymidilate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 118:29–35CrossRefPubMed

27.

Kornmann M, Schwabe W, Sander S, Kron M, Sträter J, Polat S, Kettner E, et al (2003) Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-flurouracil. Clin Cancer Res 9:4116–4124PubMed

28.

Kornmann M, Link KH, Staib L, Gaus W, Kron M, Beger H (2004) Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha. Eur J Surg Oncol 30:127

29.

Lacy AM, Garcia-Valdecasas JC, Delgado S, Castells A, Taura P, Piquet JM, Visa J (2002) Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 359:2224–2229CrossRefPubMed

30.

Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG (2003) Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 21:2912–2919CrossRefPubMed

31.

O’Connel MJ, Schaid DJ, Ganju V, Cunningham J, Kovach JS, Thibodeau SN (1992) Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis? Cancer 70:1732–1739PubMed

32.

Link KH, Staib L, Kreuser ED, Beger HG, Forschungsgruppe Onkologie Gastrointestinaler Tumoren (FOGT) (1996) Adjuvant treatment of colon and rectal cancer: impact of chemotherapy, radiotherapy, and immunotherapy on routine postsurgical patient management. RRCR 142:311–352

33.

Link KH, Staib L, Bernhart H, Kreuser ED, Suhr P, Röttinger E, Beger HG (1997) Acceptance and toxicity of postoperative adjuvant therapy in colon and rectal cancers. Interim report on the trials FOGT1 and FOGT2 of the German, Forschungsgruppe Onkologie Gastrointestinaler Tumoren (FOGT). Onkologie 20:235–238

34.

Link KH, Kornmann M, Butzer U, Leder G, Sunelaitis E, Pillasch J, Salonga D, Danenberg KD, Danenberg PV, Beger HG (2000) Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy. Cancer 89:288–296CrossRefPubMed

35.

Link KH (2003) Adjuvante Therapie des Kolonkarzinoms: 5 Jahresergebnisse der FOGT-1-Studie und neue Entwicklungen (abstract). 2nd Biebrich Interdisciplinary Conference, October 2003, Wiesbaden Germany

36.

Link KH, Mörschel M, Sagban TA, Apell V, Holtappels M, Tischbirek K (2004) Chirurgie und multimodale Therapie des Kolonkarzinoms: Evidenzbasis? Chir Gastroenterol 20:39–54CrossRef

37.

Marsoni S (1995) Fluorouracil and folinic acid in colon cancer. IMPACT Investigators. Lancet 345:1582–1583CrossRef

38.

Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedemark B (2000) Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 356:93–96CrossRefPubMed

39.

Martling A, Cedermark B, Johansson H, Rutqvist LE, Holm T (2002) The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br J Surg 89:1008–1013CrossRefPubMed

40.

Marusch F, et al (2002) Prospektive Multizenterstudien “Kolon-/Rektumkarzinome” als flächendeckende Qualitätssicherung. Chirurg 73:138–146CrossRefPubMed

41.

Matter M, Bouzourene H (2003) Lymph node metastasis and sentinel node (SD) in colorectal cancer patients. Eur J Surg Oncol 30:151

42.

McArdle CS, Hole D (1991) Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival. Br Med J 302:1501–1505

43.

Meyerhardt JA, Catalano PJ, Schrag D, Ayanian JZ, Haller DG, Mayer RJ, Macdonald JS, Benson III AB, Fuchs CS (2003) Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med 139:649–657PubMed

44.

Miller L, Emanuel D, Elfring G, Barker K, Saltz L (2002) 60-day, all-cause mortality with first-line irinotecan/fluorouracil/leucovorin (IFL) or fluorouracil/leucovorin (FL) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 21 (abstract 515)

45.

Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, et al (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 13:2936–2943PubMed

46.

O’Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Wieand HS (1997) Controlled trial of fluorouracil and low-dose leucovorin given six months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246–250PubMed

47.

O’Connell M, Laurie JA, Kahn M, Fitzgibbons RJ, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Wieand HS, Rubin J, Vukov AM, Donohue JH, Krook JE, Figueredo A (1998) Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295–300PubMed

48.

Odin E, Wettergren Y, Nilsson S, Willen R, Carlsson G, Spears CP, Larsson L, Gustavsson B (2003) Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res 9:6012–6019PubMed

49.

Porschen R, Bermann A, Loffler T, Haack G, Rettig K, Anger Y, Strohmeyer G (2001) Arbeitsgemeinschaft Gastrointestinale Onkologie. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 19:1787–1794PubMed

50.

Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Ba C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S (2000) Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 360:671–677CrossRefPubMed

51.

Qualitätssicherung in der Onkologie. Diagnostik und Therapie maligner Erkrankungen (2004) Kurzgefasste Interdisziplinäre Leitlinien. Deutsche Krebsgesellschaft, Frankfurt, ISBN 3-88603-834-3

52.

Ridwelski K, Boni C, Navarro M, Tabernero J, Bonetti A, Szanto J, Kalofonos H, Lorenzato C, Marceau-Suissa J, de Gramont A (2003) Oxaliplatin/5FU/LV (FOLFOX) as adjuvant therapy of colon cancer: results of a large randomized multicenter study (MOSAIC). Eur J Surg Oncol 30:126

53.

Safi F, Link KH, Beger HG (1993) Is follow-up of colorectal cancer patients worthwhile? Dis Colon Rectum 36:636–644PubMed

54.

Scheithauer W, Kornek GV, Marczell A, Karner J, Salem G, Greiner R, Burger D, Stoger F, Ritschel J, Kovats E, Vischer HM, Schneeweiss B, Depisch D (1998) Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer 77:1349–1354PubMed

55.

Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, et al (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 14:1735–1743CrossRefPubMed

56.

Schneebaum S, Troitsa A, Haddad R, Avital S, Kashtan H, Brazovsky E, Papo J, Skornick Y (2001) Immunoguided lymph node dissection in colorectal cancer: a new challenge? World J Surg 25:1495–1498PubMed

57.

Schorr M, Siebeck M, Zoller WG (1997) Patientenorientierte, risikoadaptierte Tumornachsorge bei Patienten mit kolorectalem Karzinom. Z Gastroenterol 35:1019–1027PubMed

58.

Schrag D, Cramer LD, Bach PB, Cohen AM, Warren JL, Begg CB (2000) Influence of hospital procedure volume on outcomes following surgery for colon cancer. J Am Med Assoc 284:3028–3035CrossRef

59.

Smith M, Gurney J, Ries GLA (1999) Cancer among adolescents 15–19 years old. In: Ries LA, Smith MA, Gurney J, et al (eds) Amon Cancer Incidence and Survival of Children and Adolescents: United States SEER Program NIH Pub. No. 99-4649. NIH, Bethesda, pp 79–90

60.

Staib L, Link KH, Beger HG (1999) Tumornachsorge bei Kolon-/Rektumkarzinom heute—Kosten-/Nutzeneffekt der nachsorge. Postgraduiertenkurs Kolon-/Rektumkarzinom 116. Kongress der Deutschen Gesellschaft für Chirurgie 1999. ISBN 3-00-004229-6

61.

Staib L, Link KH, Beger HG (2001) Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1. J Gastroenterol Surg 5:275–281CrossRef

62.

Staib L, Link KH, Blatz A, Beger HG (2002) Surgery of colorectal cancer: surgical morbidity and five- and ten-year results in 2004 patients—monoinstitutional experience. World J Surg 26:59–66

63.

Taal BG, Van Tinteren H, Zoetmulder FA (2001) Adjuvant 5FU plus levamisole in colonic or rectal cancer improvement in survival in stage II and III. Br J Cancer 85:1437–1443CrossRefPubMed

64.

James RD, Donaldson D, Gray R, Northover JM, Stenning SP, Taylor I (2003) Randomized clinical trial of adjuvant radiotherapy and 5-fluorouracil infusion in colorectal cancer (AXIS). Br J Surg 90:1200–1212CrossRefPubMed

65.

Trojan J, Povse N, Schröder O, Stein J (2002) A new immunological test strip device for the rapid, qualitative detection of faecal occult blood. Z Gastroenterol 40:921–924CrossRefPubMed

66.

Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB 3rd, Hamilton SR (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196–1206CrossRefPubMed

67.

Wein A, Lehnert T, Liersch T, Franke F, Wakker R, Hahn EG, Hohenberger W (2002) Quality controlled surgery in adjuvant treatment of colon cancer UICC III: Intact—a multicenter phase III trial. J Cancer Res Clin Oncol 12 [Suppl 1]:78

68.

Wittekind C, Meyer HJ, Bootz F (2002) UICC International Union Against Cancer TNM Klassifikation maligner Tumoren, 6. Auflage. Springer, Berlin Heidelberg Tokio New York

69.

Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fish A, Jones J, Mamounas EP, Ore L, Petrelli NJ, et al (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant chemotherapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowl Project protocol C-01. J Clin Oncol 11:1879–1887PubMed

70.

Wolmark N, Rockette H, Mamounas EP, et al (1996) The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-LEV) and 5-FU + leucovorin + levamisole (FU-LV-LEV) in patients with Dukes B and C carcinoma of the colon: first report of NSABP C04. Proc Am Soc Clin Oncol 15:205

71.

Wolmark N, Bryant J, Smith R, Grem J, Allegra C, Hyams D, Atkins J, Dimitrov N, Oishi R, Prager D, Fehrenbacher L, Romond E, Colangelo L, Fisher B (1998) Adjuvant 5-fluorouracil and leucovorin with or without interferon alpha-2a in colon carcinoma: NSABP protocol C05. J Natl Cancer Inst 90:1810–1816CrossRefPubMed

72.

Wolmark N, Rockette H, Mamounas EP, Jones J, Wieand S, Wickerham DL, Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole in patients with Dukes B and C carcinoma of the colon: Results from NSABP C04. J Clin Oncol 17:3553–3559

73.

Saini A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, Hickish T, Iveson T, Lofts F, Jodrell D, Ross PJ, Oates J (2003) Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 88:1859–1865CrossRefPubMed

Title: Colon cancer: survival after curative surgery
Authors: K. H. Link
T. A. Sagban
M. Mörschel
K. Tischbirek
M. Holtappels
V. Apell
K. Zayed
M. Kornmann
L. Staib
Publication date: 01-04-2005
Publisher: Springer-Verlag
Published in: Langenbeck's Archives of Surgery / Issue 2/2005
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-004-0508-5

At a glance: The STEP trials

Springer Medicine

Colon cancer: survival after curative surgery

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2005

The Study Centre of the German Surgical Society—rationale and current status

Synbiotics reduce postoperative infectious complications: a randomized controlled trial in biliary cancer patients undergoing hepatectomy

Comment on the publication ‘Impact of FDG-PET for staging of oesophageal cancer’ by A. Imdahl et al.

Contrast-enhanced computed tomography in acute pancreatitis: does contrast medium worsen its course due to impaired microcirculation?

Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?

April 2005